Celiac disease is a T-cell-mediated autoimmune disorder. It is relevant to us for two very different reasons. Firstly, it has a prevalence of 1 % in the European population. Thus, a huge number of celiac patients remains undiagnosed. Secondly, the celiac trigger, gluten, functions as a "switch", that has the potential to selectively activate celiac immune pathology, thereby allowing us to uncover previously unknown immune conditions. This again contributes to new celiac treatment modalities that will presumably alleviate the future fate of celiac disease patients. In 2022, the German guidelines for celiac disease are published by the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). We have summarized some of the recommendations published therein.
Thieme. All rights reserved.